Will Trump's executive order reduce drug prices?

Summary

Tangle Podcast Episode Summary
Title: Will Trump's Executive Order Reduce Drug Prices?
Host: Isaac Saul
Release Date: May 14, 2025

---

1. Introduction and Exciting Announcements

Timestamp: [02:20] – [06:09]

In this heartfelt segment, host Isaac Saul celebrates his birthday, marking six years since the inception of the Tangle Podcast. He encourages listeners to support the podcast by spreading the word or becoming members. More importantly, Isaac announces the hiring of Camille Foster as the new Editor at Large. Camille, praised for his inquisitive and open-minded political insights, will contribute to the weekly podcast, written pieces, and help shape Tangle's daily coverage. Isaac expresses pride in the growth of Tangle, now boasting 15 full and part-time employees, a significant expansion from its humble beginnings.

Notable Quote:

"He's one of the most inquisitive, open-minded, and perhaps most importantly, unpredictable political thinkers in America today. I love his brain."
— Isaac Saul [02:50]

---

2. Main Story: Trump's Executive Order on Drug Prices

Timestamp: [06:09] – [22:21]

2.1 Overview of the Executive Order

President Donald Trump introduced an executive order aimed at lowering prescription drug prices in the United States through a "Most Favored Nation" (MFN) pricing strategy. The order mandates the Secretary of Health and Human Services (HHS) to set price targets by tying U.S. drug prices to those in other OECD countries. Trump asserted that this policy would lead to immediate reductions in drug costs by 50% to 90%.

Notable Quote:

"Prescription drug prices will drop almost immediately."
— President Donald Trump [07:56]

2.2 Reactions from the Political Right

The right-wing responses are mixed but largely revolve around the feasibility and implications of the order.

• Scott McKay, American Spectator:
  McKay supports the order, arguing that it addresses the lack of a free market in U.S. prescription drugs, labeling the current system a "cartel market" where American consumers are unfairly burdened.

  Quote:

  "We are being grossly overcharged compared to the rest of the world."
  — Scott McKay [12:00]

• Michael F. Cannon, Cato Institute:
  Cannon criticizes the executive order, stating that HHS lacks the authority to impose such price controls without congressional support. He suggests alternative measures like expanding regulations to allow drug reimportation.

  Quote:

  "Price controls are never the answer."
  — Michael F. Cannon [15:30]

• Dace Potus, USA Today:
  Potus views Trump's approach favorably, noting it aligns more with free-market solutions than socialist price controls. He advocates for increased competition and lifted import restrictions to naturally lower prices.

  Quote:

  "Trump is claiming he is a man who cannot be bought...perfect vessel to usher in policies that drug companies hate."
  — Dace Potus [17:15]

2.3 Reactions from the Political Left

Left-leaning perspectives are cautiously skeptical about the efficacy and execution of the order.

• Emma Freer, MSNBC:
  Freer acknowledges the high drug prices in the U.S. but criticizes the vague nature of Trump's order, pointing out its lack of concrete measures and oversight on key players like Pharmacy Benefit Managers (PBMs).

  Quote:

  "Trump's order is so vaguely worded that it's not clear if the rules would only apply to federal programs."
  — Emma Freer [19:45]

• Bloomberg Editorial Board:
  The board highlights the complexities of drug price negotiations, emphasizing that while MFN pricing could lower U.S. costs, it might also inadvertently stifle innovation and lead to shortages.

  Quote:

  "Such a strategy could backfire for particular drugs."
  — Bloomberg Editorial Board [20:20]

• Jonathan Larson, TFN Newsletter:
  Larson argues that Trump's framework unfairly ties U.S. drug prices to European rates without addressing systemic issues like executive compensation and the true drivers of pricing.

  Quote:

  "Trump is pegging the cost of drugs here to the cost of drugs in Europe. Never mind the disparity in pharmaceutical executive compensation."
  — Jonathan Larson [21:30]

---

3. Camille Foster’s Policy Analysis

Timestamp: [22:21] – [28:08]

Camille Foster delves into the political and practical ramifications of Trump's executive order. He observes the unusual political dynamics, noting that drug price reforms are traditionally left-wing policies, making Trump's adoption of MFN pricing a significant ideological shift.

Foster acknowledges the validity of the problem—U.S. consumers pay significantly more for prescription drugs than their international counterparts. However, he expresses uncertainty about the order's practical outcomes, citing potential enforcement challenges and the opaque mechanisms of implementation.

He highlights key concerns:

• Enforcement Ambiguity:
  It remains unclear how significantly pharmaceutical companies must reduce prices to meet MFN targets or what specific enforcement actions will ensue.

• Impact on Innovation:
  There's apprehension that price controls could dampen pharmaceutical innovation and lead to drug shortages, despite the current lack of a true free market in drug pricing.

Notable Quote:

"We already don't have a free market in drug pricing, so sensible government action is necessary, but the risks are significant."
— Camille Foster [24:15]

Foster concludes that while Trump's intentions may address a real issue, the execution carries substantial risks, and historical precedents suggest that similar policies could lead to unintended negative consequences.

---

4. Questions Answered: Tariffs and Treasury

Timestamp: [28:08] – [31:26]

Laura from Michigan poses a question regarding the destination and utilization of tariff revenues collected by the government. Isaac clarifies that these funds are deposited into the Treasury's General Affairs Budget, which finances various governmental operations like employee salaries and infrastructure. Despite increased tariff revenues—reaching an all-time high of $16.3 billion in April—the federal government continues to operate with a significant deficit exceeding $1 trillion. Therefore, the additional revenue from tariffs alone is insufficient to balance the budget.

Notable Quote:

"The federal government is still running a spending deficit of over $1 trillion this fiscal year."
— Isaac Saul [30:45]

---

5. Under the Radar: Columbia River Treaty

Timestamp: [31:26] – [35:09]

Isaac highlights a lesser-known issue amid U.S.-Canada trade negotiations—the future of the 60-year-old Columbia River Treaty. This agreement governs water allocations from the Columbia River, a critical source of hydropower for both nations. Recent negotiations stalled after President Trump suggested that Canada could become the 51st U.S. state. Without a new agreement, hydropower production's reliability could be jeopardized, posing risks to energy infrastructure and regional economies.

Notable Quote:

"If a new agreement is not reached, U.S. hydropower production could become less predictable."
— Isaac Saul [32:10]

---

6. Numbers Section: Prescription Drug Statistics

Timestamp: [35:09] – [35:47]

A concise overview of key statistics related to prescription drug spending in 2022 and 2023:

• Global Spending:
  Total worldwide prescription drug spending reached $989 billion in 2022.

• U.S. Share:
  The United States accounted for 62% of this global expenditure.

• Drug Types:

  • Unbranded generics made up 90% of drug volume but only 8% of U.S. spending.
  • Brand-name originators comprised 7% of volume but 87% of spending.

• Price Multipliers:
  U.S. retail prices for selected brand-name drugs were two to four times higher than those in Australia, Canada, and France.

• Public Opinion:

  • 61% of U.S. adults take at least one prescription medication.
  • 73% believe there should be more government regulation to limit drug prices, with bipartisan support across Democrats (82%), Independents (67%), and Republicans (68%).

---

7. Have a Nice Day: Andres Munoz and Pet Rescue

Timestamp: [35:47] – [36:20]

Rising Seattle Mariners pitcher Andres Munoz partners with Seattle Area Feline Rescue to auction an experience package, including game tickets and a meet-and-greet. Inspired by his 14-year-old Persian rescue cat, Matilda, Munoz emphasizes the joy pets bring and the importance of supporting animal rescue efforts.

Notable Quote:

"Pets give you a lot of happiness. That is why it's really important for me."
— Andres Munoz [35:58]

---

Conclusion

In this episode of Tangle, Isaac Saul navigates the complex terrain of President Trump's executive order aimed at reducing prescription drug prices. Through diverse perspectives from both the political right and left, along with Camille Foster's insightful analysis, listeners gain a comprehensive understanding of the potential impacts and controversies surrounding the policy. Additionally, the podcast addresses listener questions, sheds light on lesser-known international treaties, and presents pertinent statistics that underscore the ongoing challenges in U.S. pharmaceutical pricing.

Listeners are encouraged to support Tangle by becoming members or sharing the podcast, ensuring continued independent and non-partisan political discourse.

---

Note: For more detailed information and to explore membership options, visit readtangle.com.

Transcript

[Isaac Saul]

When you're starting off with something new.

[Camille Foster]

It seems like your to do list keeps growing. Finding the right tool helps. And that tool is Shopify.

[Isaac Saul]

Shopify is the commerce platform behind millions of businesses around the world and 10% of US e commerce. And best yet, Shopify is your commerce expert with world class expertise in everything.

[Camille Foster]

From managing inventory to international shipping.

[Isaac Saul]

If you're ready to sell, you're ready for Shopify. Sign up for your $1 per month trial at shopify.com retail.

[Camille Foster]

Go to shopify.com retail Mic Check 12 Are we recording? Hi, I'm Michelle Bernstein, an award winning chef, restaurateur and mom.

[Isaac Saul]

I have a lot on my plate, including my psoriatic arthritis symptoms. That's why I was prescribed Cosentix.

[Camille Foster]

It helps me move better. Cosentyx Secukenumab is prescribed for people 2.

[Isaac Saul]

Years of age and older with active psoriatic arthritis.

[Camille Foster]

Don't use if you're allergic to Cosentyx.

[Isaac Saul]

Before starting, get checked for tuberculosis. An increased risk of infections and lowered ability to fight them may occur like tuberculosis or other serious bacterial, fungal or viral infections. Some were fatal.

[Camille Foster]

Tell your doctor if you have an.

[Isaac Saul]

Infection or symptoms like fevers, sweats, chills, muscle aches or cough had a vaccine or plan to or if inflammatory bowel disease symptoms develop or worsen serious allergic reactions and severe eczema like skin reactions may occur. Learn more at 1-844-cosentyx or cosentyx.com Ask.

[Camille Foster]

Your rheumatologist about Cosentynty.

[Isaac Saul]

Picture this. You're halfway through a DIY car fix.

[Camille Foster]

Tools scattered everywhere and boom. You realize you're missing a part.

[Isaac Saul]

It's okay because you know, whatever it is, it's on ebay. They've got everything. Brakes, headlights, cold air intakes, whatever you need. And it's guaranteed to fit. Which means no more crossing your fingers and hoping you ordered the right thing.

[Camille Foster]

All the parts you need at prices.

[Isaac Saul]

You'Ll love, guaranteed to fit and every.

[Camille Foster]

Time Ebay Things people love.

[Isaac Saul]

From executive producer Isaac Saul, this is Tangle.

[Camille Foster]

Good morning, good afternoon, and good evening and welcome to the Tangle Podcast. The place we get views from across the political spectrum, some independent thinking, and a little bit of my take. I'm your host, Isaac Sowell. Today is May 14th. It's my birthday, y' all. I say this every year. I use this occasion. The very first time that I sent a newsletter and published a podcast on my birthday, I asked that people celebrate or acknowledge my birthday by telling one or two people they knew about Tangle and becoming a member if they hadn't yet. So that was six years ago I started doing that. I'm keeping the tradition alive this year by saying, happy birthday to me. If you want to offer a birthday gift, the best thing you can do is spread the word about Tangle or go to readtangle.com membership and become a Tangle member if you haven't yet. Also, today is a far more special day than just my birthday. We sent a newsletter about this to our mailing list this morning, but we have not announced it yet. On the podcast, where it is honestly most relevant, we are hiring Camille Foster as editor at large at Tangle. If you're a regular podcast listener, you've probably heard Camille on the show a couple times in the last month or so and you probably understand why we immediately tried to poach him and bring him into the Tangle umbrella. He is, I mean, really, truly one of the most inquisitive, open minded and perhaps most importantly, unpredictable political thinkers in America today. I love his brain. I love how he thinks. I agree with him on a lot. I disagree with him on a lot. He's a media pro. He's been around the industry forever. He's succeeded at pretty much everything he's done. And I was honored and humbled by the fact that he loved Tangle and loved what we were building. And when I floated the idea to him about maybe joining the team, he was enthusiastic about it. So we're bringing Camille on. He will be editor at large. He's going to be joining the weekly podcast, the Sunday Podcast with us. He's going to be contributing written PCs to Tangle. He's going to help shape our daily coverage across platforms. It's going to be really fun. And relatedly, Camille, I realized when we put together the announcement for him, he's the 15th full or part time employee here at Tangle, which is nuts. I just have a hard time wrapping my head around that when this kind of started with just me, an Internet connection and a few hundred email subscribers. But we now have 15 people who are full or part time here at Tangle. If you are interested in seeing who those 15 people are, there will be a link in today's episode description to the full announcement about Camille joining the team. Included in that. We pulled together staff bios for everyone on the team, which was really fun to do. And yeah, it's just an amazing crew that I'm so proud of. So proud of what we're building. So many more good things to come. This is going to be an amazing year. And thank you guys for all the support that has gotten us here. Your memberships, you're listening to the episode. You're just listening to advertisements. If you're a free member, they matter. They make a huge difference. They are the reason we have enough revenue to hire people like Camille to hire the other 14 people who make up the team now. So thank you guys for that. And without further ado, I'm gonna send it over to John for today's main story, which is on Trump and some drug prices. And I'll be back for my take.

[Isaac Saul]

Thanks, Isaac, and happy, happy birth. Happy birthday, brother. I hope you get the gift that you're asking for, which is a whole bunch of membership signups and that you have a great day, my friend. And to our amazing Tangle community. Welcome, everybody. Here are your quick hits for today. First up, President Donald Trump announced a commitment by Saudi Arabia to invest $600 billion in the US via a series of deals, including an approximately $142 billion defense sales agreement. Separately, President Trump said that the US will lift its sanctions on Syria in order to give them a chance at greatness. Number two, Israel said it targeted Hamas leader in Gaza Mohammed Sinwar in an airstrike at a hospital in the southern Gaza Strip. Sinwar's status is currently unknown. Three, a federal judge ruled that the Trump administration can use the Alien Enemies act to deport accused Venezuelan gang members, but must give potential deportees at least 21 days notice and the opportunity to challenge their remote. Number four, the Trump administration said it is cutting an additional $450 million in grants to Harvard University, claiming that the school has failed to address the government's concerns about race discrimination and anti Semitic harassment on campus. And number five, the Food and Drug Administration announced it will conduct a review of ingestible fluoride prescription drug products for children with the goal of removing the products from the market. The president said in his remarks today that prescription drug prices will drop, quote, almost immediately. How realistic is that idea? Yeah, so he did say that White.

[Camille Foster]

House, they actually walked that back a little bit.

[Isaac Saul]

They actually said, we expect relief very soon and we expect the drug makers to come to the table very soon. So not exactly immediate, but there are questions on whether or not Trump will be able to get this done and whether he has the legal authority to do this. On Monday, President Donald Trump signed an executive order aimed at lowering prescription drug prices for U.S. citizens by establishing most favored nation pricing. The order directs the Secretary of Health and Human Services to facilitate price targets for pharmaceutical companies tying their prices to what consumers pay in other countries. We've been subsidizing other countries throughout the world, trump said at a White House signing ceremony on Monday, adding that some prescription drug and pharmaceutical prices will be reduced almost immediately by 50 to 80 to 90%. For context, a Most Favored Nation policy fixes domestic prices for each consumer good to match the lowest price that good is sold for. In another Organization for Economic Cooperation and Development member country, President Trump signed a similar order in 2020 implementing most favored nation pricing for prescription drugs purchased by government programs like Medicare. The order was paused following challenges in court, and the Biden administration formally revoked the rule in December 2021. Additionally, the order also directs the Secretary of Commerce and the United States Trade representative to ensure that foreign nations do not engage in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States. Trump said the order will apply to the commercial market as well as the public Medicare and Medicaid programs, but did not specify which medications it will affect. HHS Secretary Robert F. Kennedy Jr. Applauded the order, though he did not comment on when pharmaceutical companies might reduce their drug price. I think they're ready to figure out a way to get there and they have advantages in this executive order because we got rid of PBMs or pharmacy benefit managers, kennedy said. However, some industry professionals were skeptical that the order would lead to lower consumer drug prices. We're unlikely to get the drug companies to voluntarily decrease their prices and we're not going to get the other countries to voluntarily increase their prices, gerard Anderson, professor of health policy and management at John Hopkins, said. President Trump's order also faces scrutiny from some Republican lawmakers. Senate Majority Leader John Thune said a similar legislative plan would be controversial, while Senator Chuck Grassley instead expressed support for his own bill banning deceptive and unfair pricing schemes by PBMs. Today we'll cover what the right and the left are saying about Trump's executive order and then Isaac's Take Foreign.

[Camille Foster]

We'll be right back after this quick break. This episode of Tangle is brought to you by Wild Grain. Wild Grain is the first baked from frozen subscription box for artisanal breads, pastries and pastas. Wild Grain's boxes are fully customizable to your taste and dietary restrictions. In addition to their classic variety box, they recently launched a new gluten free box and a plant based box that is 100% vegan. Best of all, they take the hassle out of baking since all items bake from frozen in 25 minutes or less with no mess or cleanup. I recently got a box of Wild Grain products and included in it was their six pack of the Parmesan Herb Biscuits. These things were unbelievably delicious. They actually tasted like freshly baked bread after just throwing them in the oven for 25 minutes straight from frozen. So I can personally attest to how good some of this stuff really is. So if you are ready to bring all your favorite carbs right to your doorstep, be sure to check out Wild Grain so you can begin building your own box of artisanal breads, pastas and pastries. For a limited time only, Wild Grain is offering our listeners $30 off their first BO plus free croissants in every box when you go to wildgrain.comtangle to start your subscription. You heard me. Free croissants in every box and $30 off your first box when you go to wildgrain.comtangle. that's wildgrain.comtangle and you can use promo code Tangle at checkout. You insure your car, your phone, your home because if something bad happens, you want to be protected. But what about you? What about your income? Your family's future? PolicyGenius makes finding and buying life insurance simple, ensuring that your loved ones have a financial safety net they can use to cover debts and routine expenses. With Policygenius, you can find life insurance policies starting at just $276 a year for $1 million in coverage. It's an easy way to protect the people you love and feel good about the future. As many of you guys know, I recently had my first child and with that came the decision to get life insurance. I think everybody should have life insurance because you want to be able to cover your loved one's expenses if something happens to you. So if you need to, you can check life insurance off your to do list in no time with Policygenius. Head to Policygenius.com or click the link in the description to compare free life insurance quotes from top companies and see how much you could save. That's policygenius.com.

[Isaac Saul]

Alright, first up, let's start with what the right is saying. The right is mixed on the order, though many call it a common sense proposal. Some say the order amounts to price controls and won't meaningfully address drug prices. Others disagree and argue the proposal supports free markets. In the American Spectator, Scott McKay said Trump's drug price executive order should have happened decades ago. As Trump noted, practically every foreign country operates as a bulk buyer of pharmaceuticals, while the federal government in the US does not. Neither Medicare nor Medicaid directly dictates drug prices for their enrollees in the way that foreign countries health bureaucracies do. And naturally, private healthcare plans don't have the power to do anything of the sort, McKay wrote. What Trump is attempting to do is to play the same game those countries play to cram down drug prices. This isn't an assault on the free market. There is no free market in prescription drugs. Since World War II, it's been a cartel market and it's simply been the American people getting hammered by it. And we see this argument from the status quo crowd again and again. Trump OR MAGA or NATCONs or whoever are attacking the free market. We get this on trade again and again. Free markets are a great thing. But with respect to pharmaceuticals, Americans have been forced to subsidize drugs for the rest of the world for decades, and it's been left to the Bernie Sanderses of the world to complain about it while the rest of us are supposed to grin and bear it while Germans and Canadians get the same pills for a tiny fraction of what Ohioans and Arizonans pay, McKay said. The prescription drug market in the United states is worth $400 billion per year and we are being grossly overcharged compared to the rest of the world. Cramming down those prices and resettling the global pharmaceutical market while at the same time instituting some real reforms which decartelize the market is an idea whose time should have come a long time ago. In Cato, Michael F. Cannon criticized Trump's price controls. Trump's executive order is a laundry list of coercive actions he plans to take against drug companies that do not make significant progress towards his price targets. HHS does not have the power to impose price controls on private pharmaceutical purchases. If it did, some past administration already would have exercised that authority, cannon wrote. But Trump might be able to impose price controls even without statutory authority. Congress has granted the executive branch so much power already and so much discretion in the use of those powers and that the president may be able to claim this power that Congress never granted. What drug manufacturer would risk having hhs, doj, the ftc, Commerce, the FDA and other federal agencies simultaneously taking action against them. If Trump wants to reduce drug prices, there are several steps he can take and steps that he should push Congress to take. Price controls are never the answer, cannon said. If Trump were serious about reducing drug prices, for example, he could unilaterally implement what I recommended late last year. The administration should expand executive order 13938 from July 2020 by directing the secretary to finalize a regulation that waives the prohibition on reimportation of all classes of drugs and devices from all Organizations for Economic Cooperation and Development member nations. That one measure would reduce the trade barrier that enables the very price discrimination that vexes Trump. In USA Today, Dace Potus argued Trump's move to lower drug prices takes right approach Trump's suggestions are warmly welcome compared with the policies that many were bracing for over the weekend. When news came out that Trump was looking to attack prescription drug prices, I was nervous that the policy would come in the form of socialist price controls, potus wrote. Price controls artificially reduced the incentive for companies to create a certain product, which inevitably leads to shortages. In the case of drugs, these shortages come in two forms, the actual supply of existing drugs and the research for innovations. Drug companies have lobbied against market based approaches that eaten to their bottom line, including lifting import restrictions and reforming drug patents. Trump claims he is a man who cannot be bought and if true, that makes him a perfect vessel to usher in policies that drug companies hate, potus said. In addition to opening up drug imports, the Trump administration should look to other free market solutions to bring down drug prices. More competition rather than less would be a great place to explore cutting red tape. Lifting import restrictions and examining the terms of drug patents could also bring drug costs more in line with those of other nations over the long term. Alright, that is it for what the right is saying, which brings us to what the left is saying. The left is mixed on the order, though many say it will not achieve what Trump hopes. Some say the order is an encouraging first step but runs significant risks. Others suggest the action could actually lead to higher medication costs in the long run. In msnbc, Emma Freer said Trump's order on drug prices isn't what it seems. Trump is right that drug prices are too high. A January 2024 Rand study found that we pay nearly three times as much for prescriptions as other high income countries. Trump is also right that big pharma plays a big role in this crisis. Manufacturers game the patent process for brand name drugs to keep prices high and block more affordable generic and biosimilar options from coming to market, freer said. But there is no way to lower drug costs for American patients without costing big pharmacists whose executives can afford patio dinners at Mar a Lago and hefty donations to Trump's inauguration fund. So Trump's order so vaguely worded that it's not clear if the rules would only apply to federal programs like Medicare and Medicaid or more broadly to commercial plans. Ignores the greed inflating American pharmaceutical prices. His order, for example, has just about nothing to say about the role of pharmacy benefit managers, freer said. Additionally, Trump's order assumes Big Pharma won't just choose to raise prices charged outside the US and bringing them more in line with the inflated prices we pay. It also assumes that Trump has the power to do all this. A very big if Trump issued a similar executive order during his first term, but a federal judge blocked it for procedural reasons, the Bloomberg editorial board wrote about how to cut U.S. drug prices without hurting Innovation Policymakers have spent decades trying to lower drug prices. Most have sought incremental reforms that fail to address the root of the problem. Thanks to an accident of history, most Americans get health insurance from their employers, not the government. As a result, the US Is the only developed nation that doesn't negotiate drug prices directly. Worried that a large government buyer would suppress innovation, Congress banned Medicare from bargaining over drug prices in 2003, the board said. To be clear, that concern was well founded. High drug prices are one reason the US has become a global leader in medical innovation. Yet the lack of a single government buyer has created two main problems. First, a web of middlemen has emerged to haggle on employers behalf. Second, negotiations between these middlemen and the industry have created multiple discount prices which are guarded as confidential, the board wrote. The White House wants to use prices negotiated in other rich countries as a reference point. So called most favored nation pricing would prevent the drug industry from charging the US Any more than the lowest of these prices. The potential benefits of MFN are twofold. Not only would it tend to lower US Prices, but it would also help shift the cost of innovation by raising prices in other nations, all while moving toward a single transparent number. Of course, such a strategy could backfire for particular drugs. Prices might shift in unforeseen ways and not necessarily to the U.S. s advantage. In his TFN newsletter, Jonathan Larson argued Trump's order lowering drug prices raises drug prices out of some weird notion of fairness. Trump is pegging the cost of drugs here to the cost of drugs in Europe. Never mind the disparity in pharmaceutical executive compensation. In Trump's framing and Big Pharma's, American consumers are subsidizing low European prices. Here's how they figure that, and there is a certain capitalist logic to it, larson said. Pharmaceutical companies will only do whatever research innovation they can profit off of. Big Pharma gets you to subsidize research via the federal government, which they then cherry pick for the most profitable market winners. It's worth noting that no one is forcing drug companies to charge low prices in Europe, even if Trump does call it a scheme, which is how you badmouth negotiating tactics you can't or don't want to use. If drug companies didn't want to discount their products and weren't still making money off it, they'd just stop selling drugs there, larsen wrote. But instead of doing what Europe does, you know, negotiate better, Trump wants to preserve Big Pharma profits and just source them more evenly. But Trump's proposed system only works to Americans benefit if European prices remain low, which they won't if Trump's order is carried out. Alright, let's head over to Isaac for his take.

[Camille Foster]

All right, that is it for the left and the right are saying. Which brings us to my take. So before getting to my policy analysis of the order, I want to call out the fascinating political dynamics at play. Fixing drug prices, quite obviously is a policy proposal you would expect to come from the left. Toward the end of Biden's term, it was a policy put forward by the left and the commentary around it was robust. The ideological whiplash has caught many partisans off guard, and a seemingly infinite number of conservative pro Trump influencers have done a complete 180 on this kind of policy prescription. Now that Trump is the one proposing it, the whiplash is hitting liberal partisans too. This is a note I got from Will Kbach, our senior editor this morning who often researches the political commentary every day he said, quote, disappointingly, not many writers on the left have weighed in yet. Hard to understand why, as the drug pricing topic drove a ton of commentary toward the end of Biden's term and the left was all over it. As I looked through the opinion pages for left leaning outlets this past week, there seems to be a new level of audience capture on display just the total blanketing of Trump bashing commentary and very little thoughtful consideration of issues like this. In other words, partisans on both sides are having a hard time choosing between defending their ideology and expressing their opinion of the President, though it's easy to empathize with that disorientation, it can be difficult for any of us to find our footing when Bernie Sanders, arguably the avatar for the modern left, is advocating for legislation to further the executive agenda of Donald Trump. As for my policy analysis, I think both of these things can be true. First, the Trump administration is identifying a very real problem and using most favored Nation pricing is not an unreasonable way to address it. And number two, I'm really unsure what the practical outcome of this will be. The White House is right that the US Consumer generally pays more than three times as much for these drugs as citizens of other OECD countries. It's also correct to say that we effectively bankroll pharmaceutical research, development and innovation for the rest of the globe. The pros of this arrangement are obvious. The US Market is the first to get incredible new breakthrough treatments, and we fund all kinds of jobs and research here in the US the downside is what happens on the other end. American consumers bankroll that system, resulting in higher prices than the rest of the world pays. I am compelled by arguments like the one by Scott McKay under what the Right Is Saying, in which he convincingly makes the point that we already don't have a free market for drug prices. Trump basically is trying to play the same game other countries are already playing, which is help keep their prices down. And here in the US Opaque negotiations over these prices allow pharmaceutical companies to distort free market dynamics in ways that benefit the corporations and crush American consumers. That leads me to the practical outcomes of Trump's order. When President Biden allowed Medicare to negotiate prices for some of the drugs it covers, I laid out the many ways it could fail. It applied to a narrow scope of drugs. It didn't address the role of pharmacy benefit managers or PBMs, and drug providers would find ways to make up lost revenue, such as simply raising prices in other countries. The first round of negotiations seem to bear fruit, but the jury is still out on the policy approach as a whole. Trump's order applies to more than just Medicare drug prices and produces many of the same questions and more. For instance, what constitutes a drug manufacturer making voluntary, significant progress on reducing their prices? How much will pharmaceutical companies have to reduce their prices toward most favored nation targets to avoid the government instituting a rulemaking procedure to ensure that they do so? And what would such an enforcement process even look like? Also, since the order doesn't mention PBMs by name, how can Trump say that it cuts out the middlemen? The answer to that question is at least a little more clear. Section 4 of the Order directs the health secretary to facilitate direct to consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most favored nation price. That's at least enough to spook the industry, as shares of companies that operate PBMs sank on Monday. Health experts and pharmaceutical companies have long complained about the role of PBMs in driving up costs. And if Trump's order is able to target them effectively, it would bring the US More in line with pure countries. Of course, as with the rest of the order, Secretary Kennedy's enforcement options are entirely unclear. And perhaps most importantly, there's the same question that applies to many of Trump's other executive orders. Can he even do this? A similar order was indefinitely paused during Trump's first term. And the pharmaceutical and PBM industry has a powerful lobbying arm, which could compel a wave of lawsuits and snap Congress into slowing Trump down. I have two final points, one personal and one a broader note about the policy. First, I'm generally a believer in the power of free markets, and I'm concerned about the impact this policy will have on innovation and research here in the US but as I said above, we already don't have a free market in drug pricing. So I'm open to the government taking sensible action to address our ridiculous drug prices. And number two, plenty of experts are warning that similar policies have been tried and failed throughout American history and could lead to critical drug shortages, which is another convincing point I can't quite shake. So as much as I believe Trump is aiming at the right target, it'd be foolish to pretend there isn't any risk in taking this shot. We'll be right back after this quick break.

[Isaac Saul]

Picture this. You're halfway through a DIY car fix.

[Camille Foster]

Tools scattered everywhere, and boom. You realize you're missing a part.

[Isaac Saul]

It's okay, because, you know, whatever it is, it's on ebay. They've got everything. Brakes, headlights, cold air intake, takes, whatever you need. And it's guaranteed to fit. Which means no more crossing your fingers and hoping you ordered the right thing. All the parts you need at prices you'll love.

[Camille Foster]

Guaranteed to fit every time.

[Isaac Saul]

Ebay Things people love. Hi, it's Paige from Giggly Squad. Let's be real. Cat dads are in their golden era. Temptations, America's number one cat treat brand, is celebrating how seriously irresistible these guys are. They've got sensitivity, snack timing, precision, and their cats adore them. Add in a handful of Temptations Treats and boom, you've got a certified cat dad show. More love to the cat dad in your life with Temptations Cat Treats. And tag your fave moments with Cat dad sighting. You know we're dying to see them.

[Camille Foster]

All right, that is it for my take. Which brings us to your questions answered. This one is from Laura in Michigan. Laura said a question I think many people have. Where do the tariffs the government is collecting go exactly, I'm assuming into the Treasury. But what's the plan to spend all this extra money? Will it just go into the general budget planning or be earmarked for something else? So, yes, all of the tariffs the government collects go to the Treasury Department. As with other tax revenues, tariffs are deposited into the Treasury's General affairs budget, which finances employee salaries, infrastructure maintenance, and government goods and services. From there, it can be used for essentially anything. According to Felix Tintelnot, an associate professor of economics at Duke University, tariff revenues rose 14% from February to March $7.68 billion to $8.75 billion, and then nearly doubled in April to an all time high of $16.3 billion. And since the revenue the treasury reports has a one month lag, that number likely does not include much of the revenue collected from tariffs on China, a figure that became as steep as 145% and though it has come down to 30%, is still historically high. That's all to say that the Treasury Department is indeed collecting more money from tariffs, is still collecting that money, and is set to collect even more. However, it's not exactly extra money. The federal government is still running a spending deficit of over $1 trillion so far this fiscal year. And although the government is collecting significantly more tax revenue through tariffs, that revenue won't correct the imbalance by itself. If the Trump administration were able to cut enough spending and raise enough revenue to record a budget surplus, they would likely do what the Clinton administration did the last time the government ran a surplus from 1998 to 2001 put it towards decreasing our national debt. All right, that is it for your questions answered. I'm going to send it back to John for the rest of the pod. Don't forget if you want to give me a birthday gift, become a member to tangle or just share this podcast with somebody you know and love and we'll see you guys tomorrow. Have a good one. Peace.

[Isaac Saul]

Thanks, Isaac. Here's your under the radar story for today folks. As the United States and Canada seek a new trade deal, the future of a 60 year old treaty that governs water allocations from the Columbia river is also in question. The river runs from British Columbia through Montana, Idaho, Washington and Oregon, providing the single largest source of hydropower in the United States. Parts of the existing treaty expired shortly before the 2024 presidential election, and negotiations broke down after President Trump took office and began suggesting Canada should become the 51st US state. If a new agreement is not reached, US hydropower production could become less predictable, according to a recent non partisan congressional report. A spokesman for British Columbia said there has been no movement in negotiations since the U.S. state Department paused the discussions as part of a broad review of international commitments. The New York Times has this story, and there's a link in today's episode Description all right, next up is our numbers section. The estimated total of prescription drug spending worldwide in 2022 was $989 billion. The percentage of total prescription drug spending in 2022 accounted for by the United States was 62%. The percentage of U.S. prescription drug volume accounted for by unbranded generic drugs in 2022 was 90%, according to a 2024 RAND study. The percentage of total US prescription drug spending accounted for by unbranded generic drugs in 2022 was 8%. The percentage of US prescription drug volume accounted for by brand name originator drugs in 2022 was 7%. The percentage total of U.S. prescription drug spending accounted for by brand name originator drugs in 2022 was 87%. The average cost multiplier paid at the retail level by consumers and other payers in the United States for 20 selected brand name prescription drugs and compared to buyers in Australia, Canada and France was two to four times, according to a 2021 U.S. government Accounting Office report. The percentage of U.S. adults who say they are taking at least one prescription medication is 61%, according to a July 2023 KFF poll. The percentage of US adults who say there is not as much government regulation as there should be to limit the price of prescription drugs is 73%. And the percentage of Democrats, Independents and Republicans, respectively, who say there is not as much government regulation as there should be to limit the price of prescription drugs is 82%, 67% and 68%. And last but not least, our have a nice day story. Rising star pitcher for the Seattle Mariners and animal lover Andres Munoz partnered with Seattle Area Feline Rescue to put together an experience package to auction off for funds. The package includes passes to batting practice, game tickets and a meet and greet with Munoz. The pitcher's love of animals comes from his 14 year old Persian rescue cat, Matilda, who regularly goes on Mariners road trips. Pets give you a lot of happiness, munoz said. That is why it's really important for me. Seattle Times has this story and there's a link in today's episode description all right everybody, that is it for today's episode. As always, if you'd like to support our work, Please go to retangle.com where you can sign up for a newsletter membership, podcast membership or a bundled membership that gets you a discount on both. We'll be right back here tomorrow. For Isaac and the rest of the crew, this is John Maul signing off. Have a great day, y' all. Peace.

[Camille Foster]

Our executive editor and founder is me, Isaac Saul, and our executive producer is John Lowell. Today's episode was edited and engineered by Dewey Thomas. Our editorial staff is led by Managing Editor Ari Weitzman, with Senior Editor Will K. Back and Associate editors Hunter Casperson, Audrey Moorhead, Bailey Saul, Lindsay Knuth and Kendall White. Music for the podcast was produced by Diet75. To learn more about Tangle and to sign up for a membership, please visit our [e-mail].

[Isaac Saul]

Your business is digital.

[Camille Foster]

Why isn't your mail meet Stable, a.

[Isaac Saul]

Virtual address and mailbox that digitizes your physical mail so you can read it, act on it and manage everything from forwarding packages to depositing checks, all from Stable's secure online dashboard. Whether your team is remote or just inundated with envelopes, Stable makes it easy for operations, admin teams and founders to.

[Camille Foster]

Manage mail as scale.

[Isaac Saul]

Try [e-mail] pod to unlock 50% off your first three months of a grow or scale plan. That's usestable.com pod.

[Camille Foster]

Your business moves fast.

[Isaac Saul]

Your mail should too. This episode is brought to you by Progressive Insurance. Do you ever think about switching insurance companies to see if you could save some cash? Progressive makes it easy to see if you could save when you bundle your home and auto policies. Try [e-mail] Progressive Casualty Insurance Company and affiliates. Potential savings will vary. Not available in all states. Want a workout that actually works? Hydro delivers a full body workout that hits 86% of your muscles in just 20 minutes. Rowing with Hydro combines strength and cardio with thousands of workouts led by Olympians in breathtaking locations. No wonder nine out of ten members are still active one year later. Try Hydro risk [e-mail] and use code row to save up to $475 off your Hydro Pro rower. That's H Y-R-O-W.com code row.